hotspot -WSS

hotspot

author：focus 2025-10-02 13:51:24 - browse：255

ADAM FEUERSTEIN/STAT

CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate candidate, or ADC, called CRB-701 with the potential to be better tolerated than Padcev, an ADC treatment bladder cancer that Pfizer acquired as part of its $43 billion Seagen deal.

On Saturday, Corbus updated results from an early, dose-finding study of CRB-701, showing an overall response rate of 28% from 25 evaluable patients. Closer attention is being paid to the subset of 15 patients treated at three therapeutically active doses, where the overall response rate (all partial tumor shrinkage) was 40%. All of the responses were seen in bladder cancer (where Padcev is approved) and in cervical cancer.

The data, from a study conducted in China, were presented in a poster session at the annual meeting of the American Society of Clinical Oncology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

WSS

Why you get paid to donate plasma but not blood

Pregnancy discrimination could be enabled by AI

SCOTUS to consider access to abortion pill mifepristone

Robert Kennedy Jr.'s presidential campaign attracts GOP

US soldier in North Korean custody after crossing DMZ line

ER docs worry over extreme heat as a 'mass casualty event'

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

Biden administration sends mixed signals on US soldier who crossed into North Korea

Affirmative action in medical school literally saved lives

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

Affirmative action in medical school literally saved lives

ER docs worry over extreme heat as a 'mass casualty event'

Trump demands the U.S. pay no more for drugs than other countries … again

FDA needs staff influx to meet gene therapy needs, Marks says

Moonlake's readout produced a cash windfall. Risks remain

Supreme Court wrestles with OxyContin maker's bankruptcy deal

focus

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

Radiology is caught between AI's potential and concern for patients

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

The woman behind the Dana Farber

focus

focus

entertainment

focus